1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. ALK

ALK

ALK (Anaplastic lymphoma kinase) is encoded by the ALK gene. ALK is a membrane associated tyrosine kinase receptor of the insulin receptor superfamily. The function of the full-length ALK receptor is poorly understood. It has a probable role in the central and peripheral nervous system development and maintenance. ALK is a dependence receptor, which may exert antagonist functions, proapoptotic or antiapoptotic, depending on the absence or presence of a ligand. Dependence receptors have a potential role in cancer and development. Ligands available for this demonstration were agonist anti-ALK antibodies. ALK is still an orphan receptor, given the high level of controversy about pleiotrophin and midkine.

ALK Related Products (35):

Cat. No. Product Name Effect Purity
  • HY-50878
    Crizotinib Inhibitor 99.97%
    Crizotinib is a potent inhibitor of c-Met and ALK with an IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-12857
    Brigatinib Inhibitor 99.98%
    Brigatinib is a highly potent and selective ALK inhibitor, with an IC50 of 0.6 nM.
  • HY-12215
    Lorlatinib Inhibitor 99.83%
    Lorlatinib (PF-06463922) is a potent, dual ALK/ROS1 inhibitor, with Kis of 0.02 nM, 0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK-L1196M, respectively.
  • HY-13011
    Alectinib Inhibitor 99.84%
    Alectinib (CH5424802; RO5424802; AF802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM.
  • HY-15656
    Ceritinib Inhibitor 99.98%
    Ceritinib (LDK378) is a potent and specific ALK inhibitor with an IC50 of 0.2 nM.
  • HY-128569
    ALK-IN-5 Inhibitor
    ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK), with an IC50 of 2.9 nM.
  • HY-112801
    F-1 Inhibitor
    F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively.
  • HY-128596
    ALK-IN-6 Inhibitor
    ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK), with IC50 values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively.
  • HY-12678
    Entrectinib Inhibitor 99.32%
    Entrectinib is a potent and orally available Trk, ROS1, and ALK inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC50 values of 1, 3, 5, 12 and 7 nM, respectively.
  • HY-10192
    NVP-TAE 684 Inhibitor 99.40%
    NVP-TAE 684 is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.
  • HY-103022
    Repotrectinib Inhibitor 99.91%
    Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50s of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.
  • HY-13011A
    Alectinib Hydrochloride Inhibitor 99.95%
    Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-bind assay.
  • HY-50878A
    Crizotinib hydrochloride Inhibitor 99.86%
    Crizotinib hydrochloride is a potent inhibitor of c-Met and ALK with IC50s of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-15656A
    Ceritinib dihydrochloride Inhibitor 99.86%
    Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
  • HY-13464
    ALK-IN-1 Inhibitor 99.96%
    ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.
  • HY-103714A
    Ensartinib hydrochloride Inhibitor 98.51%
    Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
  • HY-15609
    AZD-3463 Inhibitor 98.49%
    AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
  • HY-13020
    GSK1838705A Inhibitor 98.99%
    GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC50s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC50 of 0.5 nM.
  • HY-16590
    X-376 Inhibitor 98.36%
    X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity.
  • HY-15841
    CEP-37440 Inhibitor 99.87%
    CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.